EN DE
Watch Aprogen KIC Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Aprogen KIC Inc (007460) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Aprogen KIC Inc stock KRW 1,811, price KRW 1,878, that is 3.6% below the price, quality 22 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Industrials KR · ISIN KR7007460009

AK Aprogen KIC Inc logo Thin data Nov 10, 2026

Aprogen KIC Inc

007460 · KO
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Revenue last quarter +53% vs. a year ago.
Fair value 1,811 KRW · Fairly valued
Quality 22/100
Weak Growth (revenue 5y −1.5 %/yr in KRW)
Loss-making · -60.1% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 16/100
Thin data
Estimate
Watch Aprogen KIC Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

115,425 KRW 1,720 KRW Fair Value 1,811 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 1,720 KRW – 115,425 KRW · fair‑value band 1,358 KRW – 2,263 KRW · the 1,878 KRW price screens above the 1,811 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Aprogen KIC in your weekly email

Every Wednesday you see whether Aprogen KIC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea.

Show moreShow less

The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs.

In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers.

The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 2000 and is based in Seongnam-si, South Korea.

Stock analysis

Aprogen KIC Inc (007460) currently trades at 1,878 KRW, while our estimate is 1,811 KRW, so the stock looks roughly fairly valued today (gap 3.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,358 KRW (bear) to 2,263 KRW (bull), the price of 1,878 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Industrials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Aprogen KIC Inc reported revenue of 118B KRW in FY2025 versus 141B KRW in FY2021, a compound −4.4%/yr. Reported net income was −70.2B KRW in FY2025.

Key figures

Market cap 38.6B KRW (≈ $29.0M) Micro · P/S ratio 0.30 · EPS (TTM) −3,765 KRW · Net margin −60.1% · Return on equity −30.4% · Return on assets (EBIT) −12.4% (5-year average) · Operating margin −75.7% · Revenue (TTM) 139B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 86% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 8% fair-value upside, at −4%, 007460 screens richer than that median.

Fair Value

Bear 1,358 KRW Fair Value 1,811 KRW Bull 2,263 KRW
Price 1,878 KRW · Downside -3.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 21
Debt, balance sheet and risk of trouble
Investment 56
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Start year 2020 (pandemic)
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.3% (2019) → −81.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 007460, get fair value alerts →

Compare Aprogen KIC Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Conglomerates · 349 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −3.6% · Below median
Profitability
Return on assets −9.8% · Bottom 25%
Net margin (12 months) −60.1% · Bottom 25%
Operating margin (12 months) −75.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 52.9% · Top 25%
Balance sheet
Debt / equity 0.25× · Above median

Valuation Multiplesvs Conglomerates median · lower = cheaper

P/B 0.24× · Cheapest 25%
P/S (12 months) 0.28× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 41
FUTURE (revenue growth)100 · sector 32
PAST (return on equity)0 · sector 24
HEALTH (low debt)87 · sector 90
DIVIDEND (yield)0 · sector 45

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Conglomerates stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
CITIC Limited 0267 HK$12.89 HK$25.74 +100% vs 007460
SK Inc 034730 480,000 KRW 632,391 KRW +32% vs 007460
CK Hutchison Holdings 0001 HK$71.95 HK$84.32 +17% vs 007460
Jardine Matheson Holdings J36 $61.61 $66.74 +8% vs 007460
Honeywell International Inc HON $228.22 $245.42 +8% vs 007460
SGH Limited SGH A$43.35 A$34.87 −20% vs 007460
Keppel Ltd BN4 9.76 SGD 3.87 SGD −60% vs 007460
3M Company MMM $189.37 $73.02 −61% vs 007460
Swire Pacific Limited 0019 HK$113.40 HK$27.75 −76% vs 007460
Doosan Corporation 000150 636,000 KRW 95,752 KRW −85% vs 007460

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aprogen KIC Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aprogen KIC Inc Fair Value". https://www.fairvalue-calculator.com/stock/007460

Frequently asked questions

Is Aprogen KIC Inc (007460) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,811 KRW versus a price of 1,878 KRW, about 4% lower (fairly valued).
What is the fair value of 007460?
Our estimate for Aprogen KIC Inc is 1,811 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 1,878 KRW.
What is the quality score of 007460?
Aprogen KIC Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprogen KIC Inc (007460)?
Our calculated price target is the estimate of 1,811 KRW (as of Nov 10, 2026). Cautious scenario 1,358 KRW, optimistic scenario 2,263 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Aprogen KIC Inc stock forecast for 2026?
Our estimate puts fair value at 1,811 KRW, about 4% lower versus a price of 1,878 KRW (fairly valued). Cautious scenario 1,358 KRW, optimistic scenario 2,263 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Aprogen KIC Inc (007460)?
Aprogen KIC Inc reported trailing-twelve-month revenue of about 139B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Aprogen KIC Inc (007460)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprogen KIC Inc it is 1,811 KRW per share (as of Nov 10, 2026), against a price of 1,878 KRW.
Is Aprogen KIC Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 007460 trades above its calculated fair value: price 1,878 KRW, fair value 1,811 KRW, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 007460?
No. The price is what the market pays today (1,878 KRW); the fair value is what the company's own numbers justify (1,811 KRW). For Aprogen KIC Inc the two are 67.26 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprogen KIC Inc worth?
The market values Aprogen KIC Inc at about 38.6B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 1,878 KRW; our models calculate a fair value of 1,811 KRW per share.
What do the bullish and bearish scenarios say about 007460?
Our models span a range for Aprogen KIC Inc: cautious scenario 1,358 KRW, base 1,811 KRW, optimistic 2,263 KRW per share (as of Nov 10, 2026, price 1,878 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aprogen KIC Inc (007460)?
Balance-sheet figures for Aprogen KIC Inc (as of Nov 10, 2026): return on equity −30.4%, debt of 0.25 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is 007460 from its 52-week high?
Aprogen KIC Inc trades at 1,878 KRW, about 86% below its 52-week high of 13,650 KRW and 9% above the low of 1,720 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,811 KRW is for.
Which stocks are comparable to Aprogen KIC Inc?
From the same area (Industrials) we also value 3M Company, Honeywell International Inc, Swire Pacific Limited, CITIC Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprogen KIC Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 1,878 KRW, calculated fair value 1,811 KRW (−4%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Aprogen KIC Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprogen KIC Inc (007460)?
The closing price on Nov 10, 2026 was 1,878 KRW. Our estimate is 1,811 KRW, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprogen KIC Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Aprogen KIC Inc

How large is the market capitalisation of Aprogen KIC Inc (007460)?
The market capitalisation of Aprogen KIC Inc is 38.6B KRW (≈ $29.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aprogen KIC Inc (007460)?
The price-to-sales ratio of Aprogen KIC Inc is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aprogen KIC Inc (007460)?
Earnings per share at Aprogen KIC Inc are −3,765 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aprogen KIC Inc (007460)?
The net margin of Aprogen KIC Inc is −60.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aprogen KIC Inc (007460)?
The return on equity (ROE) of Aprogen KIC Inc is −30.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprogen KIC Inc (007460)?
On an EBIT basis the return on assets of Aprogen KIC Inc is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprogen KIC Inc (007460)?
The operating margin of Aprogen KIC Inc is −75.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprogen KIC Inc (007460)?
Revenue at Aprogen KIC Inc is growing +52.9% versus a year earlier (3y avg +14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprogen KIC Inc (007460)?
Earnings per share at Aprogen KIC Inc are growing −92.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aprogen KIC Inc (007460) generate?
The free cash flow of Aprogen KIC Inc is −64.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aprogen KIC Inc (007460) carry?
The net debt of Aprogen KIC Inc is 141B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Aprogen KIC Inc in the live analysis

One click puts Aprogen KIC Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.